McKesson stock barely flinched after earnings, slipping about 1% from its recent highs, even though the company just posted the kind of pharmaceutical distribution quarter that usually gets investors’ attention. Revenue reached about US$105.4b and adjusted earnings per share climbed 20% to US$9.93, with full year adjusted EPS guidance nudged higher.

The market’s cool reaction appears at odds with those numbers. For now, traders appear to treat the move as a routine pause after a strong multi month run, rather than a reset based on the fundamentals just put on the table.

Love McKesson’s steady earnings profile but want a wider set of options that combine scale with resilience? Check out our curated list of solid balance sheet and fundamentals stocks (49 results)

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: US$105,380m vs. US$97,827m (up about 7.7%)
• Net Income, Q1 2027 vs. Q1 2026: US$614m vs. US$784m (down about 21.7%)
• Basic EPS, Q1 2027 vs. Q1 2026: US$5.17 vs. US$6.28 (down about 17.6%)
• Trailing Twelve Month Net Income, Q1 2027 vs. Q1 2026: US$4,592m vs. US$3,164m (up about 45.1%)

Tired of scrolling through dense tables and earnings figures for McKesson? For a clearer, more visual view of how the stock is valued over time, explore our company report for McKesson.

McKesson’s earnings strength backs resilient thesis

For investors who see McKesson as a healthcare infrastructure anchor, the latest quarter broadly supports that view. Revenue rose about 7.7% while adjusted EPS climbed 20%, and guidance for full year adjusted EPS moved higher. North American Pharmaceutical and Oncology & Multispecialty delivered double digit operating profit growth, which lines up with the idea of a diversified, recurring revenue engine rather than a one dimensional distributor. Trailing twelve month net income of US$4.6b versus US$3.2b a year earlier also fits the picture of a business holding its ground in core operations.

Short term profit dip keeps risk debate alive

There is still enough in these numbers to keep the bearish conversation going. Q1 net income fell about 22% and basic EPS declined nearly 18%, which tempers the otherwise strong adjusted EPS story. Medical Surgical operating profit was down in the quarter, and management flagged a mixed policy backdrop with 340B and drug pricing reforms under review. The share price slipped about 0.7% after the report, which suggests that, for now, investors are treating the strong underlying momentum and the headline and regulatory overhangs as two sides of the same coin.

Compare McKesson’s solid adjusted EPS trend and higher full year guidance with where institutional targets sit right now. See the consensus price target analysis for McKesson to check whether analysts think the stock’s recent pullback is a reset or just a breather.

Stay Ahead With Simply Wall St

If McKesson’s mix of resilient earnings and a muted share price reaction has your attention, register for free with Simply Wall St and add it to your Watchlist to track price moves against fair value and watch for a better entry point. When you do decide to take a position, manage it through the Portfolio Command Center so you only see focused, high impact updates instead of day to day noise. For longer term context, tap into the Community to see how other investors are thinking about the same risks and catalysts. This way you spot potential turning points early and give yourself a better chance to stay a step ahead of the market.

Seeking Alternatives Beyond McKesson?

Fresh stock ideas move fast. Breakout stories gain momentum, quiet compounders go flying once they get caught, and falling quality gets punished. Check these curated lists before the crowd and act now.

• Spot resilient businesses preparing for their next leg of momentum and scan our hand picked 78 resilient stocks with low risk scores while the strongest balance sheets are still under the radar for now.
• Ride the potential breakout in critical materials and review a tightly curated group from the 31 elite gold producer stocks before pricing shifts make ideal entry ranges harder to find.
• Front run the next wave of infrastructure demand and assess companies in the focused 36 power grid technology and infrastructure stocks while valuations still reflect older, slower assumptions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.